Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Johnson & Johnson | TECVAYLI (teclistamab-cqyv) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) - (MajesTEC-3) | Relapsed/refractory multiple myeloma (RRMM) | Phase 3 | Data Released | Subcutaneous | Oncology |
| Johnson & Johnson | TREMFYA (guselkumab) - (SPECTREM) | Plaque psoriasis (PsO) | Phase 3 | Data Released | Subcutaneous | Immunology: Anti-TNF |
| Johnson & Johnson | DARZALEX (daratumumab) - (ANDROMEDA) | Amyloidosis | Phase 3 | Ongoing | Intravenous | Genetic Disorder |
| Johnson & Johnson | Aticaprant - (VENTURA 1) | Adjunctive Major Depressive Disorder | Phase 3 | Ongoing | Oral | Psychiatric |
| Johnson & Johnson | ERLEADA (apalutamide) - (PROTEUS) | High Risk Prostate Cancer | Phase 3 | Ongoing | oral | Oncology |
| Johnson & Johnson | Icotrokinra (JNJ-2113) - (ICONIC-LEAD) | Moderate-to-severe psoriasis | Phase 3 | Data Released | Oral | Immunology: Anti-TNF |
| Johnson & Johnson | JNJ-2113 - (ICONIC-ADVANCE 2) | Moderate-to-severe psoriasis | Phase 3 | Ongoing | Oral | Immunology: Anti-TNF |
| Johnson & Johnson | JNJ-2113 - (ICONIC-ADVANCE 1) | Moderate-to-severe psoriasis | Phase 3 | Ongoing | Oral | Immunology: Anti-TNF |
